CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
The fifth case study to be released from CUV105, a 46-year-old male with skin type V treated with seven SCENESSE® implants and 40 NB-UVB sessions. The images demonstrate repigmentation of vitiliginous lesions on the patient’s right forearm (top) and lower legs (bottom). The patient was first diagnosed with vitiligo in 2004. The red outlines demonstrate the extent of the initially affected skin; the images are otherwise unaltered.
Format
PNG
Source
Clinuvel Pharmaceuticals Limited